ARK Investment Management LLC lowered its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 2.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,163,118 shares of the company’s stock after selling 175,329 shares during the period. […]
B & T Capital Management DBA Alpha Capital Management raised its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 40.1% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 46,149 shares of the company’s stock after acquiring an additional 13,208 shares during the period. B & […]
CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its price target hoisted by JMP Securities from $74.00 to $80.00 in a research report report published on Monday morning, Benzinga reports. JMP Securities currently has a market outperform rating on the stock. Several other research analysts also recently commented on CRSP. TD Cowen downgraded CRISPR Therapeutics from […]
CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its price objective increased by Needham & Company LLC from $85.00 to $88.00 in a research note issued to investors on Monday morning, Benzinga reports. The firm currently has a buy rating on the stock. A number of other analysts have also recently weighed in on the stock. […]
CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its target price hoisted by Needham & Company LLC from $85.00 to $88.00 in a research note released on Monday, Benzinga reports. The firm currently has a buy rating on the stock. A number of other equities research analysts also recently commented on the company. StockNews.com started coverage […]